Ibrutinib capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Imbruvica
- Company
- Pharmacyclics LLC / AbbVie
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- US indications include adult chronic lymphocytic leukemia/small lymphocytic lymphoma, including disease with 17p deletion, and adult Waldenstrom macroglobulinemia. The label also covers chronic graft-versus-host disease from age 1 year after failure of at least one systemic treatment line; this separate indication has age-specific formulation requirements.
- Indication source and scope
- US prescribing information accessed 2 November 2026. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval details and current availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.rxabbvie.com/content/dam/rxabbvie/pdf/imbruvica_pi.pdf
- Imbruvica — US prescribing information
Official prescribing information · US prescribing information accessed 2 November 2026
English primary source opened on 2 November 2026. The summary lists selected US indications, not the complete current Chinese approved scope.
- Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- FDA NDC directory — packaging reference
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
Evidence reviewed:
Open the interactive record, public price references and discussions